Low-dose H057+standard-of-care

Phase 2Small molecule

SShanghai Huilun Pharmaceutical Co., Ltd.

Low-dose H057+standard-of-care is one of 36 small molecule programs targeting Bronchiectasis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

BronchiectasisActive, not recruiting

BronchiectasisPhase 2

Active, not recruiting

Competition

Competitive Landscape

76 competitors in Bronchiectasis

#DrugCompanyPhaseTrials

Theo-Dur

Pfizer

Approved

2 2

Garamycin

SSchering-Plough

Approved

1 3

Aztreonam Lysine

Gilead

Approved

1 4

Alkeran

Symbicort

1 6

Osmitrol

BB. Braun Medical Inc.

Phase 3

1 7

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

1 8

Spiriva

Boehringer Ingelheim

Approved

1 9

Daliresp

AstraZeneca

Phase 2

4 10

Colomycin

UUniversity of Edinburgh

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Not yet recruiting

Bronchiectasis

NCT06958861

Clinical

Trials by Indication[1]

Bronchiectasis1 trial

A Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Inhaled H057 in the Treatment of Acute Exacerbations of Bronchiectasis

Not yet recruiting·SShanghai Huilun Pharmaceutical Co., Ltd.·Phase 2·NCT06958861·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Low-dose H057+standard-of-care. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Low-dose H057+standard-of-care compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Low-dose H057+standard-of-care. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Huilun Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShanghai Huilun Pharmaceutical Co., Ltd.

Low-dose H057+standard-of-care

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Bronchiectasis1 trial

References

Drug Info

Quick Facts

Related News